Pierre Blanchard1,2, Anne W M Lee3, Alexandra Carmel2,4, Ng Wai Tong3, Jun Ma5, Anthony T C Chan6, Ruey Long Hong7, Ming-Yuan Chen8, Lei Chen8, Wen-Fei Li8, Pei-Yu Huang8, Dora L W Kwong9, Sharon S X Poh10, Roger Ngan3, Hai-Qiang Mai8, Camille Ollivier2,4, George Fountzilas11, Li Zhang8, Jean Bourhis12, Anne Aupérin2,4, Benjamin Lacas2,4, Jean-Pierre Pignon2,4. 1. Department of Radiation Oncology, Gustave Roussy Cancer Campus, Université Paris-Sud, Université Paris-Saclay, Villejuif, France Gustave-Roussy, Villejuif, France. 2. Oncostat U1018 INSERM, labeled Ligue Contre le Cancer, Villejuif, France. 3. University of Hong Kong - Shenzhen Hospital, University of Hong-Kong, China. 4. Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Villejuif, France. 5. Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou 510060, China. 6. State Key Laboratory of Translational Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China. 7. National Taiwan University Hospital, Taipei, Taiwan. 8. Sun Yat-sen University Cancer Center, Guangzhou, China. 9. Department of Clinical Oncology, University of Hong Kong, Hong Kong, China. 10. National Cancer Center, Singapore. 11. Aristotle University of Thessaloniki School of Medicine, Thessaloniki, and Hellenic Cooperative Oncology Group, Athens, Greece and German Oncology Center, Limassol, Cyprus. 12. Department of Radiotherapy, Centre hospitalier universitaire vaudois, Lausanne, Switzerland.
Abstract
PURPOSE: Chemotherapy, when added to radiotherapy, improves survival in locally advanced nasopharyngeal carcinoma (NPC). This article presents the second update of the Meta-Analysis of Chemotherapy in NPC. METHODS: Published or unpublished randomized trials assessing radiotherapy (±a second chemotherapy timing) with/without chemotherapy in non-metastatic NPC patients were identified. Updated data were sought for studies included in the previous rounds of the meta-analysis. The primary endpoint was overall survival. All trials were analyzed following the intent-to-treat principle using a fixed-effects model. Treatments were classified in five subsets according to chemotherapy timing. The statistical analysis plan was pre-specified. RESULTS: Eighteen new trials were identified. Individual patient data were available for seven. In total, the meta-analysis now included 26 trials and 7,080 patients. The addition of chemotherapy reduced the risk of death, with a hazard ratio (HR) of 0.79 (95% confidence interval (CI) [0.73; 0.85]), and an absolute survival increase at 5 and 10 years of 6.1% [+3.9; +8.3] and + 8.4% [+5.7; +11.1], respectively. The largest effect was observed for concomitant + adjuvant, induction (with concomitant in both arms) and concomitant chemotherapy, with respective HR [95%CI] of 0.68 [0.59; 0.79] (absolute survival increase at 5 years: 12.3% (7.0%;17.6%)), 0.73 [0.63; 0.86] (6.0% (2.5%;9.5%)) and 0.81 [0.70; 0.92] (5.2% (0.8%;9.6%)). The benefit of chemotherapy was also demonstrated by improvement in progression-free survival, cancer mortality, locoregional control and distant control. There was a significant interaction between patient age and chemotherapy effect. CONCLUSION: This updated meta-analysis confirms the benefit of concomitant chemotherapy and concomitant + adjuvant chemotherapy, and suggests that addition of induction or adjuvant chemotherapy to concomitant chemotherapy improves tumor control and survival. The benefit of chemotherapy decreases with increasing patient age.
PURPOSE: Chemotherapy, when added to radiotherapy, improves survival in locally advanced nasopharyngeal carcinoma (NPC). This article presents the second update of the Meta-Analysis of Chemotherapy in NPC. METHODS: Published or unpublished randomized trials assessing radiotherapy (±a second chemotherapy timing) with/without chemotherapy in non-metastatic NPC patients were identified. Updated data were sought for studies included in the previous rounds of the meta-analysis. The primary endpoint was overall survival. All trials were analyzed following the intent-to-treat principle using a fixed-effects model. Treatments were classified in five subsets according to chemotherapy timing. The statistical analysis plan was pre-specified. RESULTS: Eighteen new trials were identified. Individual patient data were available for seven. In total, the meta-analysis now included 26 trials and 7,080 patients. The addition of chemotherapy reduced the risk of death, with a hazard ratio (HR) of 0.79 (95% confidence interval (CI) [0.73; 0.85]), and an absolute survival increase at 5 and 10 years of 6.1% [+3.9; +8.3] and + 8.4% [+5.7; +11.1], respectively. The largest effect was observed for concomitant + adjuvant, induction (with concomitant in both arms) and concomitant chemotherapy, with respective HR [95%CI] of 0.68 [0.59; 0.79] (absolute survival increase at 5 years: 12.3% (7.0%;17.6%)), 0.73 [0.63; 0.86] (6.0% (2.5%;9.5%)) and 0.81 [0.70; 0.92] (5.2% (0.8%;9.6%)). The benefit of chemotherapy was also demonstrated by improvement in progression-free survival, cancer mortality, locoregional control and distant control. There was a significant interaction between patient age and chemotherapy effect. CONCLUSION: This updated meta-analysis confirms the benefit of concomitant chemotherapy and concomitant + adjuvant chemotherapy, and suggests that addition of induction or adjuvant chemotherapy to concomitant chemotherapy improves tumor control and survival. The benefit of chemotherapy decreases with increasing patient age.
Authors: Anne W M Lee; Roger K C Ngan; Wai-Tong Ng; Stewart Y Tung; Ashley A C Cheng; Dora L W Kwong; Tai-Xiang Lu; Anthony T C Chan; Henry C K Sze; Harry H Y Yiu; Frank C S Wong; Kam-Tong Yuen; Rick Chappell; Horace C W Choi Journal: Cancer Date: 2020-06-04 Impact factor: 6.860
Authors: Anne W M Lee; Stewart Y Tung; Daniel T T Chua; Roger K C Ngan; Rick Chappell; Raymond Tung; Lillian Siu; W T Ng; W K Sze; Gordon K H Au; Stephen C K Law; Brian O'Sullivan; T K Yau; T W Leung; Joseph S K Au; W M Sze; C W Choi; K K Fung; Joseph T Lau; W H Lau Journal: J Natl Cancer Inst Date: 2010-07-15 Impact factor: 13.506
Authors: Edwin P Hui; Brigette B Ma; Sing F Leung; Ann D King; Frankie Mo; Michael K Kam; Brian K Yu; Samuel K Chiu; Wing H Kwan; Rosalie Ho; Iris Chan; Anil T Ahuja; Benny C Zee; Anthony T Chan Journal: J Clin Oncol Date: 2008-12-08 Impact factor: 44.544
Authors: Wing Lok Chan; James Chung Hang Chow; Zhi-Yuan Xu; Jishi Li; Wing Tung Gobby Kwong; Wai Tong Ng; Anne W M Lee Journal: Front Oncol Date: 2022-02-01 Impact factor: 6.244